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Abstract S100A4 (Mts1) is a Ca2+-binding protein of the S100
family. This protein plays an important role in promoting tumor
metastasis. In order to identify S100A4 interacting proteins, we
have applied the yeast two-hybrid system as an in vivo approach.
By screening a mouse mammary adenocarcinoma library, we
have demonstrated that S100A4 forms a heterocomplex with
S100A1, another member of the S100 family. The non-covalent
heterodimerization was confirmed by fluorescence spectroscopy
and electrospray ionization Fourier transform ion cyclotron
resonance mass spectrometry. Mutational analysis revealed that
replacement of Cys76 and/or Cys81 of S100A4 by Ser abolishes
the S100A4/S100A1 heterodimerization, but does not affect the
S100A4 homodimerization in vivo. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Members of the S100 family have been implicated in a wide
range of cellular processes including cell growth and di¡er-
entiation, signal transduction, microtubule dynamics, cyto-
skeleton organization and cell motility [1,2]. The S100 pro-
teins utilize two helix-loop-helix motifs, known as EF-hands,
for calcium-binding [3]. The most puzzling feature of the S100
proteins is their link with di¡erent human diseases. Deregu-
lated S100 expression is associated with breast cancer and
melanoma, metastasis, Alzheimer’s disease, cardiomyopathies,
psoriasis and cystic ¢brosis [2]. For this reason, the S100
proteins are widely used as molecular markers in pathology
[4,5].
The biological e¡ects mediated by the S100 proteins are
determined by their interaction with cellular targets. Over
the past few years, signi¢cant progress has been made towards
identifying the target proteins that could relay regulatory sig-
nals of the S100 family members. This search revealed that
cytoskeleton proteins [6,7], transcription factors [8], kinases [9]
and annexins [10] are potential targets for S100.
The S100A4 protein is believed to be involved in triggering
the cascade of events that lead to the metastatic phenotype of
tumor cells. The level of S100A4 expression strongly corre-
lates with the metastatic potential of di¡erent mouse tumors
[11,12] and it was recently demonstrated by two di¡erent
transgenic mouse models that overexpression of the S100A4
transgene causes an increase of the metastatic ability of breast
tumors [13,14]. However, the molecular mechanism of the
S100A4 action is not yet completely understood.
Here, we applied the yeast two-hybrid system as an in vivo
approach to screen a mouse mammary adenocarcinoma
cDNA library for S100A4 interacting proteins. The screening
revealed the homodimerization of S100A4 as well as the in-
teraction of S100A4 with another member of the S100 family,
S100A1.
2. Materials and methods
2.1. GAL4-activating domain cDNA library construction
cDNA was synthesized on poly(A) mRNA isolated from the
CSML-100 mouse mammary adenocarcinoma cell line using oligo-
(dT)12 primer and cloned into the Hybri-ZAP phage vector (Hybri-
ZAP two-hybrid vector kit, Stratagene). The library was ampli¢ed
and converted into plasmids by the mass excision procedure according
to the manufacturer’s protocol.
2.2. The pBD-S100A4 bait plasmid
The open reading frame of the mouse S100A4 gene (exons II^III)
was cloned in-frame with the GAL4 DNA-binding domain into the
yeast expression vector pBD-GAL4/Cam (Stratagene) as follows: the
pBD-GAL4/Cam plasmid was digested with EcoRI, £ushed with the
Klenow fragment of DNA polymerase I and redigested with SalI. The
S100A4 cDNA insert was generated by digesting the p271 plasmid
[11] with NcoI, £ushing with the Klenow polymerase and redigesting
with SalI. The S100A4 cDNA was ligated with the pBD-GAL4/Cam
vector resulting in the pBD-S100A4 bait plasmid. The construct was
veri¢ed by dideoxy chain termination sequencing. Expression of the
bait protein in yeast was con¢rmed by Western blotting with a mono-
clonal anti-S100A4 antibody.
2.3. Yeast transformation
The Saccharomyces cerevisiae strain YRG-2 (MATK ura3-52 his3-
299 ade2-101 lys2-801 trp1-901 leu2-3 112 gal4-542 gal80-538
LYS2: :UASGAL4-TATAGAL1-HIS3 URA3: :UASGAL4-TATACYC1-
lacZ) (Stratagene) was used for all assays. Yeast cultures were grown
at 30‡C in either YPD medium (2% peptone, 1% yeast extract, 2%
glucose) or SD minimal medium (0.67% nitrogen base, 18.2% D-sor-
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bitol, 2% glucose, supplemented with amino acids). Transformation of
yeast was performed using the YRG-2 Yeast Competent Cell kit
(Stratagene) according to the manufacturer’s protocol. Yeasts trans-
formed with pBD-S100A4 along with the GAL4-transactivating do-
main cDNA library were grown on SD agar plates lacking Trp, Leu
and His. After 3^7 days, the HIS3 positive colonies were streaked on
either a new SD agar plate without Trp, Leu, His or on a nitrocellu-
lose membrane (Hybond C, Amersham Pharmacia Biotech) placed on
a SD agar plate without Trp and Leu and grown for 1 or 3 days,
respectively, at 30‡C. The ¢lter L-galactosidase assay was performed
according to the protocol of Stratagene. The time required for color
development ranged from 1 h to overnight.
2.4. Mutagenesis
All mutations were introduced into S100A4 by polymerase chain
reaction (PCR) using the pBD-S100A4 plasmid as a template with the
following primers: Cys76CSer reverse: 5P-GACAGAGTACTCCTG-
GAAGTC-3P ; Cys81CSer forward: 5P-TTCCTGTCCTCCATTGC-
CATG-3P ; Cys86CSer reverse: 5P-GAATTCATTGGACATCATG-
GC-3P ; Cys93CSer forward: 5P-TTTGAGGGCTCCCCAGA\T-
AAG-3P ; Phe72CAla forward: 5P-GCCCAGGAGTACTGTG-
TCTTCCT-3P ; Phe72CAla reverse: 5P-GTCAACTTCATTGTC-
CCTGT-3P ; vLeu79 forward: 5P-TCCTGCATTGCCATGATGTG-
CA-3P ; vLeu79 reverse: 5P-GAAGACACAGTACTCCTGGA-3P.
PCR ampli¢cation was performed using a 10:1 AmpliTaq (Perkin
Elmer):PfuI (Stratagene) polymerase mixture. PCR products were
eluted from an agarose gel, self-ligated and used for transformation
of the XL-1 Escherichia coli strain. All constructs were veri¢ed by
dideoxy chain termination sequencing [15].
2.5. Protein expression and puri¢cation
For overexpression of the recombinant S100 proteins in E. coli
M15, the T5 RNA polymerase promoter-based expression vector
pQE30 (Qiagen) was used. Expression of recombinant proteins was
induced at an A600 value of 0.7 by 1 mM isopropyl-1-thio-L-D-galac-
topyranoside. The bacteria were harvested after 4 h by centrifugation.
The pellet obtained from 2 l of bacterial culture was resuspended in 50
ml of 10 mM Tris^HCl pH 7.5, 0.1 M sucrose and frozen at 380‡C.
To purify the recombinant S100 proteins, the cell suspension was
thawed and diluted 2-fold with 100 mM Tris^HCl, pH 7.5, 400 mM
NaCl, 1 mM EDTA, 10 mM dithiothreitol. The ¢nal suspension was
sonicated with 8 bursts of 15 s at the maximum amplitude with 30 s
intervals. The sonicated sample was centrifuged at 16 000Ug for 30
min. The resulting supernatant was brought to 5 mM of CaCl2 and
applied to a Phenyl-Sepharose column (Amersham Pharmacia Bio-
tech) equilibrated with 50 mM Tris^HCl, pH 7.5, 150 mM NaCl,
5 mM CaCl2. The recombinant proteins were eluted with 50 mM
Tris^HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, concentrated using
Filtron 10K and their puri¢cation was completed by size exclusion
chromatography. The purity of all proteins was determined by sodium
dodecyl sulfate (SDS)^PAGE and mass spectrometry and their dimer-
ic state was con¢rmed by analytical ultracentrifugation. Analytical
centrifugation was performed as described in [16].
2.6. Fluorescence spectroscopy
Steady-state £uorescence experiments were carried out on a Fluo-
roMax spectro£uorimeter equipped with a circulating water bath.
Tryptophan speci¢c excitation wavelength 295 nm was used. All read-
ings were corrected for dilution and contribution of tyrosine emission
of S100A4.
2.7. Electrospray ionization Fourier transform ion cyclotron resonance
(ESI-FTICR) mass spectrometry
Mass spectrometry measurements were made using a FTICR mass
spectrometer (Bruker Daltonics, Billerica, MA, USA) equipped with a
shielded 9.4T super-conducting magnet (Magnex Scienti¢c Ltd.,
Abingdon, UK), a cylindrical ‘in¢nity’ ICR cell with diameter
d = 0.06 m and an external ESI source (Analytica of Branford, Bran-
ford, USA) as described previously [17]. The ESI source was equipped
with a capillary made of pyrex, coated on both ends with nickel.
Solutions of S100A1 and S100A4 at equimolar concentrations (typi-
cally 20 WM) were sprayed at room temperature from 5 mM ammo-
nium acetate bu¡er (pH 6). Carbon dioxide was used as a drying gas
in the electrospray source.
3. Results
The yeast two-hybrid system for screening cDNA encoding
cellular proteins that are able to interact with a protein of
interest has been applied in a large number of studies. It
was successfully applied to study protein^protein interactions
in complex biological processes such as cell proliferation, dif-
ferentiation, apoptosis and intracellular signal transduction
[18^20].
To identify proteins which could interact with S100A4, we
co-transfected the YRG-2 yeast strain with the bait plasmid
pBD-S100A4 and the CSML-100 mouse adenocarcinoma
cDNA library. The interaction phenotype was scored by the
ability of the transformed yeast to grow on a synthetic me-
dium without histidine and by L-galactosidase activity. From
2U106 transformants, 287 colonies grew on a selective me-
dium lacking histidine. Of these 287 colonies, 53 revealed L-
galactosidase activity in a ¢lter assay. Plasmid DNA from
these colonies was isolated and subcloned in E. coli. All res-
cued plasmids were then re-introduced into the yeast along
with pBD-S100A4 to verify interactions and to exclude false
positives. Only 41 out of 53 originally isolated clones grew on
Table 1
Mutation analysis of the S100A4/S100A1 interaction using the yeast two-hybrid system
Bait (BD-GAL4 fusion) Prey (AD-GAL4 fusion) HIS3 phenotype L-Gal phenotype
S100A4 S100A4 + blue
S100A1 + blue
S100A4-Phe72CAla S100A4 3 white
S100A1 3 white
S100A4-vLeu79 S100A4 3 white
S100A1 3 white
S100A4-Cys76;81;86;93CSer S100A4 + blue
S100A1 3 white
S100A4-Cys86;93CSer S100A4 + blue
S100A1 + blue
S100A4-Cys76;81CSer S100A4 + blue
S100A1 3 white
S100A4-Cys76CSer S100A4 + blue
S100A1 3 white
Yeast clones co-transfected with the GAL4 DNA-binding domain (BD) and GAL4 transcriptional activation domain (AD) hybrid constructs
were ¢rst grown on SD medium without Trp and Leu (selection for the plasmids) and then streaked onto a SD plate lacking histidine or on a
nitrocellulose membrane. The HIS3 phenotype was scored after 3 days. L-Galactosidase activity was analyzed by a ¢lter assay using 5-bromo-
4-chloro-3-indoxyl-L-D-galactopyranoside as a substrate.
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the selective medium without histidine. The corresponding
cDNA was subjected to sequencing analysis.
Forty out of 41 clones were identi¢ed as the S100A4 cDNA
fused in-frame with GAL4-AD, indicating the homodimeriza-
tion of S100A4 in vivo. Besides the S100A4 dimers, one of the
clones was identi¢ed as a cDNA encoding the S100A1 pro-
tein. To verify the interaction, the plasmids were transfected
into yeast pairwise either with pBD-S100A4 and pLamin C or
pBD-GAL4/Cam as controls. The S100A1 transfected yeast
demonstrated S100A4 dependent transcription of the reporter
genes, indicating the interaction (not shown).
To probe the region of S100A4 that is essential for hetero-
dimerization, we tested several S100A4 mutant proteins for
the interaction with S100A1 using the yeast two-hybrid sys-
tem. The point mutations Phe72CAla and vLeu79, which
were shown to abolish the homodimerization of S100A4 (Tar-
abykina, S. et al., submitted), also a¡ected the S100A4 inter-
action with S100A1 (Table 1). We have explored the cysteine
scanning, since it was previously demonstrated for another
S100 protein, S100B, that cysteines may play a role in S100
protein^protein interactions [21]. All four cysteines in S100A4
were replaced by serine in di¡erent combinations (Table 1).
None of cysteines was essential for the S100A4 homodimeri-
zation. However, we have found that Cys76 and/or Cys81 play
an important role in the S100A4/S100A1 heterodimerization.
Two other cysteine residues Cys86 and Cys93 did not show any
in£uence on the heterodimer formation in vivo.
An attempt was made to demonstrate homo- and heterodi-
merization of S100A4 and S100A1 by anion-exchange chro-
matography. Puri¢ed preparations of S100A4 and S100A1
were mixed and incubated without denaturation, then concen-
trated and fractionated on a Resource Q column. Several
distinct peaks were detected (Fig. 1A). Two of them eluting
at 50 mM NaCl and 180 mM NaCl were shown to be the
S100A4 and S100A1 homodimers, respectively. The inter-
mediate peak was very small and contained both S100A4
and S100A1 proteins. Only S100 monomers were observed
on the SDS gel, which was run under non-reducing condi-
tions, indicating the absence of covalently linked dimers
(Fig. 1B). Although we had expected to see both protein spe-
cies in the S100A4/S100A1 heterodimer in 1:1 ratio, the in-
tensity of the S100A1 band was weaker than that of S100A4.
To explain this observation, both proteins were applied onto
an SDS gel in the same amounts (according to the Bradford
assay and UV absorbance spectroscopy) and stained with
Coomassie R250. We found that the staining intensities of
the equal amounts of two recombinant proteins are di¡erent
(not shown).
Direct evidence for the S100A4/S100A1 heterodimerization
was obtained in vitro by ESI-FTICR mass spectrometry.
Under appropriate conditions, the ESI technique allows the
transportation of intact multisubunit complexes from their
natural aqueous environment into the gas phase. We have
previously applied ESI-FTICR mass spectrometry for the de-
tection and characterization of the dimeric homocomplexes of
both calmodulin and S100A4 ([22], Scott, D. et al., submit-
ted). Here, we report the ¢rst direct observation of a hetero-
complex formed between S100A1 and S100A4. Fig. 2 shows
the ESI-FTICR mass spectrum obtained for an equimolar
mixture of S100A1 and S100A4 in ammonium acetate bu¡er,
pH 6. The ultra-high mass resolution obtained with the
FTICR mass spectrometer allowed the isotopic resolution of
each of the peaks observed and revealed that several di¡erent
species were present. Signals corresponding to the species with
the average masses of 11 864.16 and 13 117.45 Da, respec-
tively, were observed and indicated the presence of both
monomeric S100A1 and monomeric S100A4 proteins. How-
ever, the most abundant signal detected at m/z 2271 was
found to correspond to the species carrying 11 charges with
Fig. 1. Puri¢cation of the S100A1/A4 heterocomplex. A: S100A1
and S100A4 were obtained by overexpressing in E. coli. Proteins
were puri¢ed as described in Section 2. To get heterocomplex, both
proteins (S100A1/A4 molar ratio was 2:1) were incubated in 20
mM Tris^HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.5 at room tem-
perature for 30 min. The mixture was concentrated with a Filtron
10K microconcentrator to a ¢nal volume of 0.2 ml, diluted to 2 ml
with 20 mM Tris^HCl, pH 7.5 (bu¡er A) and loaded on a 1 ml Re-
source Q10 column (Pharmacia) equilibrated with a same bu¡er.
The elution was performed with a gradient of bu¡er B (bu¡er A+2
M NaCl). The £ow rate was 2 ml/min and fractions of 2 ml were
collected. B: The proteins were analyzed by 10% non-reduced Bis^
Tris SDS^PAGE (Novex) in MES running bu¡er pH 7.3, followed
by staining with Coomassie blue.
Fig. 2. ESI mass spectrum of S100A1 and S100A4 proteins sprayed
from an aqueous 5 mM ammonium acetate bu¡er, pH 6.0.
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the average mass of 24 982.00 Da. This is in agreement with
the average mass 24 981.61 Da that could be predicted from
the individual monomer masses for a non-covalent heterodi-
meric complex between S100A1 and S100A4. Signals corre-
sponding to non-covalent homodimeric complexes of both
S100A1 and S100A4 were also observed, as indicated in Fig.
2.
The presence of the unique tryptophan residue (W90) in the
C-terminus of S100A1 allowed us to apply the £uorescence
spectrometry technique to monitor the S100A1^S100A4 inter-
action by changes in tryptophan £uorescence. Addition of
calcium to 1 mM caused a red shift of the S100A1 £uores-
cence emission spectrum by 4 nm and an increase in the £uo-
rescence intensity at 351 nm indicating that W90 became ex-
posed to the solvent. Addition of saturating amounts of
S100A4 resulted in a decrease in the intensity of the trypto-
phan emission and a slight blue shift suggesting that W90
moved towards a more hydrophobic environment (Fig. 3).
In the absence of calcium, the quenching e¡ect caused by
S100A4 was not accompanied by a shift in the emission max-
imum of the single tryptophan of S100A (not shown). These
observations suggest that the interaction occurs both in the
presence and in the absence of calcium, however, the mecha-
nisms of the S100A4/S100A1 complex formation are di¡erent.
4. Discussion
Two-hybrid screening of the CSML-100 mouse mammary
adenocarcinoma library revealed that the metastasis-promot-
ing S100A4 (Mts1) protein forms a heterocomplex with
S100A1, another member of the S100 family. Mutation of
the conservative residues Phe72 and Leu79 in S100A4 abol-
ished both the homodimerization of S100A4 and the interac-
tion with S100A1. This was expected since these residues are a
part of the hydrophobic core and seem to be important for
the integrity of the S100 proteins [23]. Surprisingly, the
S100A4/S100A1 interaction was completely abolished when
Cys76 or/and Cys81in the S100A4 protein were replaced by
Ser. This mutation had no e¡ect on the S100A4 homodi-
merization, suggesting that the mechanism of the S100A4/
S100A1 heterodimerization could be di¡erent from that of
the homodimerization of S100A4. Dissociation of the
S100A4/S100A1 complex into subunits in the presence of
SDS under non-reducing conditions indicated that cysteine
disul¢des are not involved in the complex formation.
Our £uorescence spectrometry data suggest that in the pres-
ence of calcium the tryptophan residue in S100A1 becomes
part of a hydrophobic cluster in the S100A1/S100A4 hetero-
dimer but is exposed in the S100A1 homodimer. The hetero-
dimerization does not absolutely require calcium. Further in-
vestigation is therefore necessary to understand how the S100
complexes are formed and assembled in the presence and in
the absence of calcium. According to the recently published
three-dimensional structures of the S100A6 [23] and S100B
[24] proteins, monomer^monomer interfaces are dominated
by interactions between helices I, IP, IV and IVP, whereas
putative dimer^dimer interactions may occur via hydrophobic
residues in the C-terminal domain, which are exposed in the
presence of calcium. Gribenko and Makhatadze [25] suggested
that in the S100P protein Cys85 and Tyr88, which are located
besides the helix IV, are possibly involved in the formation of
oligomerization interface. Taking these observations together,
we have to exclude a single, simple model. It is most likely
that the intermolecular interaction of the S100 subunits re-
quires two di¡erent recognition surfaces. One of these surfaces
could be speci¢cally designed for canonical dimer formation
[23] and the other for the interaction with target molecules or
for the formation of oligomers. It may well be that heterodi-
merization of S100 proteins requires formation of higher or-
der oligomeric intermediates for the subunit exchange. Per-
haps, the mutations Cys76CSer and/or Cys81CSer abolish
the formation of such putative intermediates and therefore
prevent heterodimerization of S100A4/S100A1.
Members of the Sl00 family are known to be multifunc-
tional proteins. However, little is known about the mecha-
nisms that regulate the diversity of the S100 functions. The
heterodimerization seems to be one of such mechanisms as
there are several examples where homo- and heterodimers of
S100 demonstrate di¡erent biological e¡ects. For instance, the
S100A1/S100B (KL) heterodimer has been shown to inhibit the
assembly of brain microtubule proteins in the presence of
zinc, while the S100A1 (KK) homodimer had no such e¡ect
[26]. Another example of the S100 heterodimerization is the
complex formed by S100A8 (calprotectin or MRP8) and
S100A9 (MRP14). Newton and Hogg demonstrated that
although the S100A9 protein stimulates neutrophil adhesion
mediated by L-integrin Macl, the adhesion could be inhibited
by S100A8 through the formation of the S100A8/S100A9 het-
erodimer [27]. The heterodimeric complex between S100B and
S100A6 has recently been reported by Yang et al. [28]. The
heterodimerization was demonstrated by the yeast two-hybrid
system and con¢rmed by immunoprecipitation from melano-
ma cell lysates. However, the biological e¡ects of this inter-
action are not known.
We provide here the ¢rst evidence for the interaction be-
tween S100A1 and Sl00A4 (Mts1). The biological signi¢cance
of this interaction remains to be determined. We have found
that S100A4 and S100A1 are co-expressed in several analyzed
mouse adenocarcinoma cell lines (not shown), indicating that
there is a probability that the S100A4/S100A1 heterodimer-
ization may have a functional meaning. One can hypothesize
Fig. 3. Overlap between corrected £uorescence spectra of apo-
S100A1, holo-S100A1 (calcium bound form) and heterocomplex
S100A1/A4. Solid line, apo-S100A1; dotted line, holo-S100A1;
dashed line, S100A1/S100A4 complex. All spectra were obtained at
20‡C in 10 mM Tris^HCl pH 7.5, 100 mM KCl and 500 nM of
S100A1. The excitation wavelength was 295 nm. The spectrum of
holo-S100A1 was recorded in the presence of 1 mM CaCl2. See the
text for further details.
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that the heterodimer can have cellular targets di¡erent from
those of the S100A4 and S100A1 homodimers.
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